Pharmacogenetics of *ugt* genes in North African populations

M. Gaibar1 · A. Novillo1 · A. Romero-Lorca1 · M. E. Esteban2,3 · A. Fernández-Santander1

Received: 2 October 2017 / Revised: 9 March 2018 / Accepted: 14 May 2018 / Published online: 31 July 2018
© The Author(s) 2018. This article is published with open access

What we already know

Cytochrome P450 (CYP450), sulfotransferase (SULT), and glucuronidase (UGT) enzymes play roles in the phase I and phase II metabolism of most clinically prescribed drugs. As polymorphisms in these genes may alter enzyme activities, most prescribed drugs will differ in their efficacy and side effects. In prior work, we showed that besides polymorphisms in *CYP450*, those in *SULT* and *UGT* also give rise to different serum levels of some drug metabolites than detected in wild-type carriers of the genes [1]. To date, most pharmacogenetic studies have examined Asian and Caucasian populations and although the pharmacogenetics of *CYP450* genes has been explored in sub-Saharan countries, scarce data exist for African genetic variations in *SULT* and *UGT* [2, 3].

Africans show an extremely high incidence of malaria, tuberculosis, and HIV/AIDS, along with a growing rate of noncommunicable diseases, especially diabetes, and hypertension [4]. Data concerning these diseases and others indicate a wide diversity of prevalence and mortality rates among African countries. Although therapeutic drugs have improved life expectancies in many countries, most drugs have been associated with adverse drug reactions (ADRs) [4]. As CYP450 enzymes metabolize antiretrovirals, antimalarials, and antipsychotics, knowledge of their genetic variability could be useful for clinicians. In some developed countries, a high economic burden of deaths has been attributed to ADRs whereas no such estimates exist for African populations. This lack of data highlight a need to improve knowledge on ADRs in Africa, mainly when these effects are associated with drugs used to treat the main killer diseases in this continent. Knowledge such as this is essential to develop and implement pharmacogenetic tests both in developing and developed countries.

Africans show the broadest genetic variability of all human populations. This is because the African origin of mankind has meant a longer time period for genetic diversity in Africans compared to non-Africans. For example, according to known CYP450 variability, 90% of clinically relevant *CYP2C8, CYP2C19*, and *CYP2D6* variants occur within the range of 0–24% [5]. North African ethnicities have been largely overlooked regarding the detection of genes involved in drug metabolism such as SULTs and UGTs. Besides their genetic variability, African populations are characterized by their remarkable linguistic and cultural diversity, consistent with the huge diversity of landscapes and habitats of this continent. Current North African cultures (from Morocco to Egypt) have an ancient Berber background with influences from several civilizations of different historical times. The Arabs settled permanently in North Africa and although they persuaded Berbers to adopt Islam, some large Berber groups in Morocco, Algeria, and Tunisia have retained their Berber language and customs and avoided mixed marriages until today. Prior studies of the genetic variability of these North African groups have detected vast genetic heterogeneity and a lack of genetic groupings by either geographical or linguistic criteria [6]. This considerable genetic variability has been previously reported for *CYP3A4, CYP3A5, SULT1A1, SULT1A2*, and *SULT1E1* in North African populations [7].

Here, we stress the importance of assessing the frequencies of CYPs, SULTs, and UGTs in North African populations because of their role in the metabolism of many drugs and their association with various types of cancer. In ongoing work, we have been looking at the UGT mutations *UGT1A4* Pro24Thr (*rs6755571*), *UGT1A4* Leu48Val (*rs2011425*), *UGT2B7* His268Tyr (*rs7439366*), *UGT2B15* Asp85Tyr (*rs1902023*), *UGT2B15* Lys523Thr (*rs4148269*), and *UGT2B17*del in populations from Morocco, Libya,
Tunisia, and Algeria. Some variants seem to confer reduced UGT activity, for instance, the UGT2B15 85Tyr allele in response to oxazepam and lorazepam and UGT1A448Val and UGT2B7268Tyr with effects on tamoxifen metabolism [8, 9]. In contrast, no effects of the UGT2B17 deletion have been detected on oxazepam and androgenic steroid substrate availability, perhaps owing to the possible duplication event origin of UGT2B15 and UGT2B17, which show similar sequence identity [10].

North African populations

The groups examined in this work underway comprise the general population representative of two Moroccan Berber localities (Asni region in the High Atlas and Sidi Bouhria in the northeast Atlas), one Algerian Berber region and different areas of Tunisia and Libya. Four hundred and eighty-four DNA samples—collected from healthy, unrelated individuals (both sexes) aged 18–60 years and native to the regions they lived in (at least three generations)—were processed as previously described [7]. All subjects signed an informed consent form approved by the ethics committees of the Universities responsible for sample collection (Chouaib Doukkali University in Morocco, Monastir University in Tunisia, and Abderrahmane Mira Bejaia University in Algeria). Individuals from Tunisia and Libya were Arabic speaking, whereas the Moroccan and Algerian subjects sampled spoke Berber.

UGT polymorphisms

The allelic variants UGT1A424Thr, UGT1A448Val, UGT2B7268Tyr, UGT2B1585Tyr, UGT2B15523Thr, and UGT2B17del were genotyped as described in Romero-Lorca et al. [9] using conventional quantitative polymerase chain reaction and polymerase chain reaction-restriction fragment length polymorphism techniques. Allele frequencies were estimated through direct gene counts. Hardy–Weinberg equilibrium was assessed using an exact test. North African data were compared with data available for European and Sub-Saharan African populations from the 1000Genomes database (http://www.1000Genomes.org) using the pairwise population differentiation test included in Arlequin v.3.5 (http://cmpg.unibe.ch/software/arlequin35/). Genetic diversities were estimated using Nei’s formula [11].

Associated risks or functional roles

The association between some gene polymorphisms and the presence of functional role- or risk associated phenotypes
a relevant issue when studying such diverse groups as North African populations. Given marked differences in CYP, SULT, and UGT polymorphisms between Caucasian and Sub-Saharan African groups and their relevance both in drug pharmacogenetics and risks of various types of cancer, detailed study of the frequencies of these mutations is needed to improve clinical decision-making in African healthcare institutions. In prior work, we detected a 2–3 times higher frequency of CYP3A4*1B associated with prostate cancer in North Africans compared with European Caucasians (Table 2), peaking at 29% in Moroccan Berbers [7]. Some SULT gene alleles are also important because of both their link to endometrial cancer and their high frequency in some areas of North Africa. For instance, the SULT1A1*2 allele appears in ~50% of northeast Atlas Moroccan Berbers (Table 2) [7].

Given these marked ethnic differences in CYP and SULT genes and their association with drug pharmacogenetics and disease risk, UGT gene polymorphisms must also be considered in population studies because of their known influence in the metabolism of some drugs such as lorazepam and tamoxifen [8, 9]. The higher frequency of the UGT1A448Val mutation (26% in some Moroccan areas; Table 1) relative to those reported in Caucasians is especially remarkable. Indeed, the wt homozygous genotype UGT1A4Leu/Leu has been linked to a better efficacy of lamotrigine (epileptic drug used in pediatric patients) [12]. The UGT2B1585Tyr allele, which appears in up to 45% of individuals in some North African areas, is a high-activity allele possibly associated with a reduced prostate cancer risk according to increased rates of androgen glucuronidation leading to lower intraprostate androgen levels (Table 2) [13]. It has also been reported that patients homozygous for the UGT2B1585Tyr mutation show a significantly lower mean apparent oral oxazepam clearance rate compared with wt/wt patients [14]. The UGT2B17 allele deletion appeared at a rate worth considering though within the reported range for other populations despite the variation observed among ethnic groups, e.g., rates of 21% and 33%, respectively, described for African Americans and Caucasians [15]. Women with both copies of the UGT2B17 gene deletion show an increased risk of lung adenocarcinoma associated with decreased NNAL (tobacco-specific metabolite of nitrosamine) glucuronidation rates [16]. Further, a reduced risk of colorectal cancer has been described in Caucasian men homozygous for UGT2B17del [17]. This last link has been related to the preferred metabolism of UGT2B17 over that of certain nonsteroidal anti-inflammatory drugs and over flavonoids with antioxidant properties, such that individuals lacking UGT2B17 may have higher levels of these protective dietary components [17].

The variation ranges of CYP, SULT, and UGT genes observed in the North African populations are considerably

| Polymorphism SNP | Genotype | Allele frequency range in North African populations | Ref. |
|------------------|----------|-----------------------------------------------|-----|
| CYP3A4*1B | Allele *1B | 11–29 % [7] | [7] |
| SULT1A1*2 | Allele *2 | 10–47 % [7] | [7] |
| SULT1E1*2 | Allele *2 | 6–16 % [7] | [7] |
| UGT1A448Val | Homozygous wt/wt allele (48 Leu) | 2–26 % | [12] |
| UGT2B1585Tyr | Homozygous 85Tyr | 35–45% [13, 14] | [13, 14] |
| UGT2B17del | Homozygous del/del | Null allele: complete loss of UGT2B17 activity | [16] |
| UGT2B17del | Homozygous del/del | Increased risk of lung adenocarcinoma in women: associated with decreased NNAL glucuronidation rates. | [16] |
| UGT2B17del | Homozygous del/del | Reduced risk of colorectal cancer: associated with higher levels of antioxidant protective dietary components. | [17] |
higher than those reported for European Caucasians. Given
the known links of some of these polymorphisms both with
ADRs and the risk of some cancer types, studies are
urgently needed to improve knowledge of the prevalence
of these allelic variants. Future studies are also required
to examine the impact of these genetic variants on different
drugs in terms of their availability, metabolism, and efficacy.
This will be a good starting point to develop pharmacogenetic tests for use in clinical practice that will
avoid unnecessary costs to healthcare systems. The infor-
mation arising from these studies will have useful implica-
tions for healthcare professionals both in developing
countries and in other countries when managing patients
of North African origin.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.

References

1. Novillo A, Romero-Lorca A, Gaibar M, Rubio M, Fernández-
Santander A. Tamoxifen metabolism in breast cancer treatment:
taking the focus off the CYP2D6 gene. Pharm J. 2017;17:109–11.
2. Masimirembwaba C, Dandara C, Leutcher PD. Rolling out efavir-
enz for HIV precision medicine in Africa: are we ready for
pharmacovigilance and tackling neuropsychiatric adverse effects?.
OMICS. 2016;20:575–580.
3. Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwaba C,
Novel variants of major drug-metabolising enzyme genes in
diverse African populations and their predicted functional effects.
Hum Genom. 2009;3:169–90.
4. Dandara C, Swart M, Mpeta B, Wonkam A, Masimirembwaba C,
Cytochrome P450 pharmacogenetics in African populations:
implications for public health. Expert Opin Drug Metab Toxicol.
2014;10:769–85.
5. Alessandri M, Asfaha S, Dodgen TM, Warnich L, Pepper MS,
Cytochrome P450 pharmacogenetics in African populations. Drug
Metab Rev. 2013;45:253–75.
6. Gaibar M, Esteban E, Harich N, Kandil M, Fernández-Santander
A. Genetic differences among North African Berber and Arab-
speaking populations revealed by Y-STR diversity. Ann Hum
Biol. 2011;38:228–236.
7. Fernández-Santander A, Novillo A, Gaibar M, Romero-Lorca A,
Moral P, Sánchez-Cuenca D, et al. Cytochrome and sulfotransferase gene variation in North African populations. Pharma-
cogenomics. 2016;17:1415–23.
8. Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, et al.
Effect of the UGT2B15 genotype on the pharmacokinetics,
pharmacodynamics, and drug interactions of intravenous lor-
azeepam in healthy volunteers. Clin Pharmacol Ther. 2005;77:
486–94.
9. Romero-Lorca A, Novillo A, Gaibar M, Bandrés F, Fernández-
Santander A. Impacts of the glucuronidase genotypes UGT1A4,
UGT2B7, UGT2B15 and UGT2B17 on tamoxifen metabolism in
breast cancer patients. PLoS ONE. 2015;10:e0132269
10. Turgeon D, Carrier JS, Lévesque E, Beatty BG, Bélanger A, Hum
DW, Isolation and characterization of the human UGT2B15 gene,
localized within a cluster of UGT2B genes and pseudogenes on
chromosome 4. J Mol Biol. 2000;295:890–90.
11. Nei M. Molecular Evolutionary Genetics. New York: Columbia
University Press; 1987. P.
12. Du Z, Jiao Y, Shi L, Association of UGT2B7 and UGT1A4
polymorphisms with serum concentration of antiepileptic drugs in
children. Med Sci Monit. 2016;22:4113
13. MacLeod SL, Nowell S, Plaxco J, Lang NP, An allele-
specific polymerase chain reaction method for the determination of the
D85Y polymorphism in the human UDP-glucuronosyltransferase
2B15 gene in a case-control study of prostate cancer. Ann Surg
Oncol. 2000;7:777–82.
14. He X, Hesse LM, Hazarika S, Masse G, Harmatz JS, Greenblatt
DJ, et al. Evidence for oxazepam as an in vivo probe of
UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y
polymorphism but unaffected by UGT2B17 deletion. Br J Clin
Pharmacol. 2009;68:721–30.
15. Wilson W, 3rd .Pardo-Manuel de VF, Lyn-Cook BD, Chatterjee
PK, Bell TA, Detwiler DA, et al. Characterization of a common
deletion polymorphism of the UGT2B17 gene linked to
UGT2B15. Genomics. 2004;84:707–14.
16. Gallagher CJ, Muscat JE, Hicks AN, Zheng Y, Dyer AM, Chase
GA, et al. The UDP-glucuronosyltransferase 2B17 gene deletion
polymorphism: sex-specific association with urinary 4-(methyl-
nitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype
and risk for lung cancer. Cancer Epidemiol Biomark Prev.
2007;16:823–8.
17. Angstadt AY, Berg A, Zhu J, Miller P, Hartman TJ, Lesko SM,
et al. The effect of copy number variation in the phase II detox-
ification genes UGT2B17 and UGT2B28 on colorectal cancer
risk. Cancer. 2013;119:2477–85.